[Management of myelodysplastic syndromes].

Abstract excerpt

Myelodysplastic syndromes are heterogeneous diseases whose molecular characteristics have only been identified in recent years. Better identification of prognostic factors, larger access to allogeneic stem cell transplantation and the advent of new drugs notably hypomethylating agents (azacitidine, decitabine) and lenalidomide have improved patient outcome.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anemia
• Share to Antineoplastic Agents
• Share to Cellular Microenvironment